The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | IFM 209 update: 4-year extended follow-up of transplantation outcomes in myeloma
Aurore Perrot, MD, University of Toulouse, Toulouse, France, discusses the results of a 4-year extended follow up of the IFM 2009 study (NCT03679351) comparing lenalidomide, bortezomib and dexamethasone (RVd) therapy to RVd plus high-dose melphalan and autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma patients. With a median follow-up of over 90 months, the findings from 700 patients agreed with earlier results of significantly superior progression-free survival in the transplant arm, compared to RVd treatment alone. Measurable residual disease-negativity rates were also higher in the transplant group and were predictive of extended progression-free survival. Most patients who had disease progression in the RVd alone arm underwent delayed ASCT. There was no significant difference in overall survival between the two groups after 8 years, nor in the incidence of second primary malignancies. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
